ALIM


Here’s Why Cowen Upgraded Alimera Sciences Inc (ALIM) Shares

With near-term financing overhang removed and more confident in Iluvien’s sales growth, Cowen analyst Boris Peaker upgrades shares of Alimera Sciences Inc (NASDAQ:ALIM) from Market …

Friday’s Biotech Roundup: Merrimack Pharmaceuticals Inc (MACK), Juno Therapeutics Inc (JUNO), Alimera Sciences Inc (ALIM), Relypsa Inc (RLYP)

Merrimack Pharmaceuticals Inc Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares closed down over 6% Friday, after the cancer drug maker reported second-quarter results, with net Onivyde sales …

Cowen Remains Cautious on Alimera Sciences Inc (ALIM) Following 2Q:16 Results

In a research report released Tuesday, Cowen analyst Boris Peaker reiterated a Market Perform rating on shares of Alimera Sciences Inc (NASDAQ:ALIM), with a …

Cantor Sees 72% Upside For Alimera Shares As Commercial Rollout Going Well

Cantor analyst Caroline Corner initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM) with a Buy rating and a $10 price target, which represents a potential upside of 72% …